Literature DB >> 897347

Linear and nonlinear assessment of tolmetin pharmacokinetics.

J W Ayres, D J Weidler, E Sakmar, J G Wagner.   

Abstract

Plasma concentration-time data in man after oral dosing of the nonsteroidal antiinflammatory agent, tolmetin sodium, were fitted to both linear and nonlinear pharmacokinetic equations. The apparent elimination half-life of tolmetin is shown to be 4.5 to 6.0 hours. An analytical method is presented which allows measurement of plasma concentrations for at least 32 hr (compared with a previous limit of about 8 hr) after a single oral dose of the equivalent of 400 mg of tolmetin acid.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 897347

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  6 in total

Review 1.  Tolmetin: a review of its pharmacological properties and therapeutic efficacy in rheumatic diseases.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-06       Impact factor: 9.546

2.  Pharmacokinetics of tolmetin with and without concomitant administration of antacid in man.

Authors:  J W Ayres; D J Weidler; J MacKichan; E Sakmar; M R Hallmark; E F Lemanowicz; J G Wagner
Journal:  Eur J Clin Pharmacol       Date:  1977-12-28       Impact factor: 2.953

Review 3.  Non-steroidal anti-inflammatory analgesics other than salicylates.

Authors:  R N Brogden
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of drugs used in juvenile arthritis.

Authors:  K J Skeith; F Jamali
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

Review 5.  Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.

Authors:  J H Lin; D M Cocchetto; D E Duggan
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs.

Authors:  R K Verbeeck; J L Blackburn; G R Loewen
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.